Pepscan, the all-in-one peptide service provider with proprietary constraining technologies, is excited to announce that its specialists will manufacture the personalized peptide pools for the treatment of cancer patients in Evaxion’s phase IIb trial. Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, recently published the initial results of the peptide-based personalized therapy EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. Pepscan had provided the personalized peptide pools for its phase I/IIa trial. The Denmark-based biotechnology company is currently preparing its phase IIb study, which is expected to start in 2022 at various sites in Europe, the US and Australia.
“We are very excited to learn that the personalized peptides we manufactured for Evaxion have seen positive effects in cancer patients treated in the clinic. We consider our collaboration with Evaxion to be a perfect example of how combining Evaxion’s expertise in the development of AI-driven immunotherapies and Pepscan’s track record in the reliable supply of personalized peptide pools brings us closer to potential life-improving breakthroughs,” says Hans de Backer, CEO of Pepscan. “We are very pleased to continue to work with Evaxion on the next phase of its clinical journey.”